Celsis Acquires In Vitro Technologies, Expanding Services for ADME Studies

The acquisition of Rweality will strengthen Enosium Life Science’s market access and medical-economic development strategies.

EsoBiotec’s proprietary lentiviral platform primarily enables the immune system to attack cancers but could ultimately offer patients cell therapy treatments delivered in minutes rather than several weeks.

The transaction includes abelacimab, which is a late-stage medicine that is in development for prevention of stroke and systemic embolism in patients with atrial fibrillation.

The transaction adds a pipeline of early-stage drug candidates against high-value targets to Telix’s portfolio, along with other novel targets currently in the discovery stage.

The transaction, which was first announced in September 2024, expands Phillips Medisize’s inhalation drug delivery capabilities.

In the latest of a series of acquisitions this year, AbbVie will acquire Nimble Therapeutics, which includes that company’s lead asset, an oral peptide for treating psoriasis.